

**ASX Code: GSS**

23 August 2018

## **Additional tax incentive of A\$0.4m following understatement of FY17 Research and Development claim**

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) advises that it expects to receive an additional cash refund from the Australian Taxation Office (“ATO”) of A\$0.4m from an amendment to the 2017 financial year (“FY17”) tax return. Genetic Signatures expects to receive the cash payment from the ATO this quarter, which will strengthen its cash balance of A\$9.0m (as at 30 June 2018).

The additional claim was identified during preparation of the 2018 financial year (“FY18”) Research and Development (“R&D”) claim. As a result, Genetic Signatures will restate the FY17 financial results.

- ENDS -

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**

**Chief Executive Officer**

john@geneticsignatures.com

T: +61 (0)2 9870 7580

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.